Window of Opportunity Trial of Neoadjuvant Olaparib and Durvalumab for Triple Negative or Low ER+ Breast Cancer

Condition:   Breast Neoplasms Interventions:   Drug: Olaparib;   Drug: Durvalumab Sponsors:   Seoul National University Hospital;   AstraZeneca Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials